Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Drug Updates

  |  Issue: May 2009  |  

Michele Kaufman is a freelance medical writer based in New York City.

References

  1. Coffey J. FDA petition letter to remove propoxyphene from the market. Published December 5, 2008; www.ashp.org/DocLibrary/Advocacy/Propoxyphene.aspx. Accessed April 8, 2009.
  2. Traynor K. Close vote by FDA advisers favor propoxyphene withdrawal. Published March 2, 2009; www.ashp.org/import/news/HealthSystemPharmacyNews/newsarticle.aspx?id=3037. Accessed April 8, 2009.
  3. FDA. Transdermal drug patches with metallic backings. Published March 5, 2009; www.fda.gov/medwatch/safety/2009/safety09.htm#Transdermal. Accessed April 8, 2009.
  4. FDA. FDA warns about wearing medicated patches during MRIs. Published March 5, 2009; www.fda.gov/bbs/topics/NEWS/2009/NEW01967.html. Accessed April 8, 2009.
  5. FDA. Raptiva (efalizumab). Published April 8, 2009; www.fda.gov/medwatch/safety/2009/safety09.htm#Raptiva. Accessed April 13, 2009.
  6. Sedghizadeh PP, Stanely K, Caliguir M, Hofkes S, Lowry B, Shuler CF. Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: An institutional inquiry. J Am Dent Assoc. 2009;140:61-66.
  7. Edwards BJ, Hellstein JW, Jacobsen PL, et al. Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: An advisory statement from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc. 2008;139:1674-1677.
  8. Wysowski D. Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med. 2009;360:89-90.
  9. Chustecka Z. Esophageal cancer in patients taking oral bisposphonates. Published December 31, 2008; www.med scape.com/viewarticle/586127. Accessed April 8, 2009.
  10. FDA. Potential signals of serious risks/new safety information identified from the Adverse Event Reporting System (AERS) between January–March 2008. Updated February 4, 2009; www.fda.gov/Cder/aers/potential_signals/potential_signals_2008Q1.htm. Accessed April 8, 2009.
  11. Fischer A. FDA posts drugs under review over possible safety concerns. Published February 5, 2009; www.firstwordplus.com/Fws.do?articleid=AE4EA7AB7202473B8DC3548A74AA4F57&logRowId=282534. Accessed April 8, 2009.
  12. Paddock C. FDA approves first gout drug for 40 years. Published February 16, 2009. www.medicalnewstoday.com/articles/139130.php. Accessed April 8, 2009.
  13. FDA approves Genzyme’s Synvisc-One for osteoarthritis of the knee. Published February 26, 2009; www.genzyme.com/corp/investors/GENZ%20PR-022609.asp. Accessed April 8, 2009.
  14. Additional strengths of Avinza available. Published February 5, 2009. www.empr.com/Additional-strengths-of-Avinza-available/article/126905. Accessed April 8, 2009.
  15. Scytera Foam available for chronic psoriasis. Published January 26, 2009. www.empr.com/Scytera-Foam-available-for-chronic-psoriasis/article/126384. Accessed April 8, 2009.
  16. UCB receives complete response letter from US FDA for use of Cimzia in rheumatoid arthritis patients. Published January 5, 2009; www.pharmasentry.com/news/newsletter.cfm?linkid=B1776F25-1372-54C2-6119BA974B2E09CC. Accessed April 8, 2009.
  17. UCB’s meeting with U.S. FDA defines path forward for Cimzia in rheumatoid arthritis. Published February 6, 2009; www.ucb.com/news/newsdetail.asp?newsid=1287988. Accessed April 8, 2009.
  18. Acurox tablets new drug application accepted for filing with a priority review classification. Published March 3, 2009; www.globenewswire.com/newsroom/news.html?d=160640. Accessed April 8, 2009.

Related Articles

    Diagnosis, Management of Medication-Induced Osteonecrosis of the Bone

    Prior to the widespread use of bisphosphonates for the manage­ment of osteoporosis, multiple myeloma and metastatic cancer to the skeletal system, osteonecrosis of the jawbones was an infrequent condition seen after radiation for oral cancers (osteoradionecrosis) and in chronic odontogenic infections.1 Since the mid-2000s, osteonecrosis of the jawbones has been noted to occur as a…

    Reading Rheum

    Handpicked Reviews of Contemporary Literature

    Do Bisphosphonates Reduce Cardiovascular-Related Mortality?

    It is well known that hip fractures are associated with significant morbidity and mortality: Mortality increases 15–25% in the year following a hip fracture.1–5 We know that treating osteo­porosis prevents fractures and improves patient survival. But is there a relationship beyond this? Several studies have found that bisphosphonate therapy is associated with a reduction in…